210 related articles for article (PubMed ID: 33683524)
21. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
22. Updated EORTC QLQ-C30 general population norm data for Germany.
Nolte S; Waldmann A; Liegl G; Petersen MA; Groenvold M; Rose M;
Eur J Cancer; 2020 Sep; 137():161-170. PubMed ID: 32777715
[TBL] [Abstract][Full Text] [Related]
23. The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events.
Kawaguchi T; Azuma K; Sano M; Kim S; Kawahara Y; Sano Y; Shimodaira T; Ishibashi K; Miyaji T; Basch E; Yamaguchi T
J Patient Rep Outcomes; 2017; 2(1):2. PubMed ID: 29757309
[TBL] [Abstract][Full Text] [Related]
24. Exploring the patient experience of locally advanced or metastatic pancreatic cancer to inform patient-reported outcomes assessment.
Herman JM; Kitchen H; Degboe A; Aldhouse NVJ; Trigg A; Hodgin M; Narang A; Johnson CD
Qual Life Res; 2019 Nov; 28(11):2929-2939. PubMed ID: 31273624
[TBL] [Abstract][Full Text] [Related]
25. Comparison of EORTC quality of life core questionnaire (EORTC-QLQ-C30) and gastrointestinal quality of life index (GIQLI) in patients undergoing elective colorectal cancer resection.
Schwenk W; Neudecker J; Haase O; Raue W; Strohm T; Müller JM
Int J Colorectal Dis; 2004 Nov; 19(6):554-60. PubMed ID: 15205989
[TBL] [Abstract][Full Text] [Related]
26. A brief instrument to measure health-related quality-of-life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10).
Marschner N; Wilke J; Reschke D; Kaiser F; Schmoor C; Grugel R; Boller E
J Med Econ; 2018 Sep; 21(9):920-929. PubMed ID: 29874105
[TBL] [Abstract][Full Text] [Related]
27. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events.
Gilbert A; Piccinin C; Velikova G; Groenvold M; Kuliś D; Blazeby JM; Bottomley A
J Clin Oncol; 2022 Nov; 40(32):3770-3780. PubMed ID: 35973158
[TBL] [Abstract][Full Text] [Related]
28. Psychometric validation of the Moroccan version of the EORTC QLQ-C30 in colorectal Cancer patients: cross-sectional study and systematic literature review.
El Alami Y; Essangri H; Majbar MA; Boutayeb S; Benamr S; El Malki HO; Souadka A
BMC Cancer; 2021 Jan; 21(1):99. PubMed ID: 33499819
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
30. Choice of a patient-reported outcome measure for patients with anal cancer for use in cancer clinical trials and routine clinical practice: a mixed methods approach.
Gilbert A; Francischetto EO; Blazeby J; Holch P; Davidson S; Sebag-Montefiore D; Velikova G
Lancet; 2015 Feb; 385 Suppl 1():S38. PubMed ID: 26312860
[TBL] [Abstract][Full Text] [Related]
31. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.
Reeve BB; McFatrich M; Mack JW; Maurer SH; Jacobs SS; Freyer DR; Withycombe JS; Baker JN; Castellino SM; Lin L; Lucas NR; Hinds PS
J Natl Cancer Inst; 2020 Nov; 112(11):1143-1152. PubMed ID: 31999349
[TBL] [Abstract][Full Text] [Related]
32. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research.
Giesinger JM; Loth FLC; Aaronson NK; Arraras JI; Caocci G; Efficace F; Groenvold M; van Leeuwen M; Petersen MA; Ramage J; Tomaszewski KA; Young T; Holzner B;
J Clin Epidemiol; 2020 Feb; 118():1-8. PubMed ID: 31639445
[TBL] [Abstract][Full Text] [Related]
33. Development of computerised adaptive testing (CAT) for the EORTC QLQ-C30 dimensions - general approach and initial results for physical functioning.
Petersen MA; Groenvold M; Aaronson NK; Chie WC; Conroy T; Costantini A; Fayers P; Helbostad J; Holzner B; Kaasa S; Singer S; Velikova G; Young T;
Eur J Cancer; 2010 May; 46(8):1352-8. PubMed ID: 20231085
[TBL] [Abstract][Full Text] [Related]
34. The Azeri Version of European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30): Translation and Validation.
Davudov MM; Harirchi I; Amiraliyev N; Mehtiyeva E; Mirzajani Z; Amiraliyev K; Rustamli N; Zebardast J; Montazeri A
Asian Pac J Cancer Prev; 2020 Jan; 21(1):267-271. PubMed ID: 31983195
[TBL] [Abstract][Full Text] [Related]
35. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.
Bergman B; Aaronson NK; Ahmedzai S; Kaasa S; Sullivan M
Eur J Cancer; 1994; 30A(5):635-42. PubMed ID: 8080679
[TBL] [Abstract][Full Text] [Related]
36. Comparing the patients' subjective experiences of acute side effects during radiotherapy for head and neck cancer with four different patient-reported outcomes questionnaires.
Holländer-Mieritz C; Johansen J; Johansen C; Vogelius IR; Kristensen CA; Pappot H
Acta Oncol; 2019 May; 58(5):603-609. PubMed ID: 30698098
[No Abstract] [Full Text] [Related]
37. Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers.
Günther M; Hentschel L; Schuler M; Müller T; Schütte K; Ko YD; Schmidt-Wolf I; Jaehde U
BMC Cancer; 2023 Jul; 23(1):629. PubMed ID: 37407982
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
39. Cross-Sectional Patient-Reported Outcome Measuring of Health-Related Quality of Life With Establishment of Cancer- and Treatment-Specific Functional and Symptom Scales in Patients With Penile Cancer.
Draeger DL; Sievert KD; Hakenberg OW
Clin Genitourin Cancer; 2018 Dec; 16(6):e1215-e1220. PubMed ID: 30201215
[TBL] [Abstract][Full Text] [Related]
40. Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure.
Feldman E; Pos FJ; Smeenk RJ; van der Poel H; van Leeuwen P; de Feijter JM; Hulshof M; Budiharto T; Hermens R; de Ligt KM; Walraven I
ESMO Open; 2023 Feb; 8(1):100775. PubMed ID: 36652781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
